Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 4/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.40 |
| ▸ | MERTK | Q12866 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085216 | 0.91 | GPR119 (0.43) | CCND1CDK6MERTKPOLB | |
| SCHEMBL3969687 | 0.90 | TYRO3 (0.42) | CCND1CDK6MERTKFLT3TYRO3 | |
| Hydrochloric Acid SCHEMBL4089417 | 0.90 | FGFR1 (0.44) | CCND1CDK6MERTKFLT3TYRO3 | |
| Hydrochloric Acid SCHEMBL4079945 | 0.85 | TYRO3 (0.40) | CCND1CDK6DYRK2MERTKFLT3 | |
| Hydrochloric Acid SCHEMBL3965318 | 0.83 | CDK1 (0.45) | CCND1CDK6MERTKFLT3TYRO3 | |
| SCHEMBL3964769 | 0.82 | FGFR1 (0.45) | MERTKFLT3TYRO3AXLGAS6 | |
| SCHEMBL3969362 | 0.82 | MAPT (0.42) | MERTKTP53LMNAPOLB | |
| SCHEMBL3969289 | 0.82 | FGFR1 (0.44) | ACKR3 | |
| SCHEMBL3966644 | 0.82 | LMNA (0.42) | MERTKTP53LMNAPOLB | |
| SCHEMBL3971646 | 0.82 | MERTK (0.41) | MERTKTP53LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | ACKR3 2346/4885CCND1 1420/4885CDK6 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.